8例新型冠状病毒肺炎死亡病例临床特征分析

doi:10.3969/j.issn.1006-3110.2020.09.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (4519 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨8例新型冠状病毒肺炎(简称新冠肺炎)死亡病例的死亡原因及可能危险因素。方法回顾性分析自2020年1月23日—2月25日在武汉市第五医院住院期间死亡的8例新冠肺炎病例的临床特征。结果 8例新冠肺炎病例的死亡年龄在65~75岁之间,平均年龄(70.63±3.99)岁,平均病程 (12±2.83)d;8例病例均有明确基础疾病,其中最常见为高血压,其次为脑梗死、糖尿病、冠心病、肺部基础疾病;除肺脏损害外,其他器官损害主要有心脏,其次为肾脏、肝脏,凝血系统功能紊乱,其中4例(4/8)病例D2聚体明显升高;白细胞计数升高6例(6/8)、中性粒细胞计数升高6例(6/8)、C反应蛋白(C-reactive protein, CRP)升高8例(8/8)、降钙素原(procalcitonin, PCT)升高8例(8/8)、淋巴细胞计数下降4例(4/8)、淋巴细胞百分比下降8例(8/8)。病例死亡前一次白细胞计数(8/8)、中性粒细胞计数(8/8)、CRP(8/8)、降钙素原(8/8)、D2聚体(8/8)水平较入院时升高,血氧分压(8/8)、淋巴细胞计数(7/8)、淋巴细胞比率(8/8)较入院时降低,差异有统计学意义(P<0.05)。胸部CT显示肺部影像学较入院时病灶增多、范围增大。结论高龄及合并有基础疾病是新冠肺炎抢救困难甚至死亡的重要危险因素,细菌感染可能对疾病进展起着重要促进作用,血氧分压、胸部CT、白细胞计数、中性粒细胞计数、淋巴细胞计数、淋巴细胞百分比、CRP、降钙素原、D2聚体可能是疾病进展、预后不良的重要参考指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	石清红
	龚子龙
	吴越
	李倩
	马丹
	蔡航航

关键词 ：新型冠状病毒肺炎, 死亡, 临床特征

Abstract：Objective To explore the death causes and possible risk factors of 8 death cases with coronavirus disease 2019 (COVID-19). Methods We retrospectively analyzed the clinical characteristics of 8 COVID-19 cases which died duringhospitalization from January 23 to February 25 in 2020. Results The 8 death cases with COVID-19 were between the ages of 65 and 75, the mean age was (70.63±3.99) years and the average course of disease was (12±2.83) days. All the 8 death cases had underlying diseases, and the most common disease was hypertension, followed by cerebral infarction, diabetes, coronary heart disease and underlying diseases related to lung. Besides lung damage, heart, kidney and liver damages and coagulation dysfunction were also observed, and the level of D-dimer increased significantly in 4 (4/8) death cases. Leukocyte and neutrophil counts and the levels of C-reactive protein (CRP) and procalcitonin (PCT) were elevated in 6(6/8), 6(6/8), 8(8/8) and 8(8/8) cases, respectively. Lymphocyte count declined in 4 (4/8) cases, and lymphocyte percentage in 8 (8/8) cases. The levels of leukocyte (8/8), neutrophil (8/8), PCT (8/8) and D-dimer (8/8) in the last test before death were increased as compared with those in the first test during hospitalization, whereas the level of PaO2 (8/8), lymphocyte count (7/8) and lymphocyte percentage (8/8) were decreased as compared with those in the first test during hospitalization, showing statistically significant differences (all P<0.05). Chest CT showed an increased number and range of lung lesions as compared with admitting hospital. Conclusions Advanced age and underlying diseases are the important risk factors for the difficulty of COVID-19 rescue and even death, and bacterial infection may play an important role in promoting the progression of the disease. Pa02, chest CT, the counts of leukocyte, neutrophil and lymphocyte, lymphocyte percentage, CRP, PCT and D-dimer may be used as important reference indicators for disease progression and poor prognosis.

Key words： coronavirus disease 2019 death clinical characteristic

收稿日期: 2020-03-11

R563.1+4

通讯作者: 蔡航航,E-mail:515996943@qq.com。

作者简介: 石清红(1988-), 女, 硕士研究生, 医师,主要从事呼吸系统疾病研究工作。

引用本文:

石清红, 龚子龙, 吴越, 李倩, 马丹, 蔡航航. 8例新型冠状病毒肺炎死亡病例临床特征分析[J]. 实用预防医学, 2020, 27(9): 1032-1036. SHI Qing-hong, GONG Zi-long, WU Yue, LI Qian, MA Dan, CAI Hang-hang. Clinical characteristics of 8 death cases with coronavirus disease 2019. , 2020, 27(9): 1032-1036.

链接本文:

https://www.syyfyx.com/CN/10.3969/j.issn.1006-3110.2020.09.003 或 https://www.syyfyx.com/CN/Y2020/V27/I9/1032

[1] Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019[J].N Engl J Med, 2020,382(8):727-733.
[2] World Health Organization.Naming the coronavirus disease (COVID-19) and the virus that causes it [EB/OL]. (2020-02-11)[2020-02-25]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
[3] 国家卫生健康委员会. 截至3月30日24时新型冠状病毒肺炎疫情最新情况[EB/OL]. (2020-03-31)[2020-03-31]. http://www.nhc.gov.cn/xcs/yqtb/202003/ec2689b0e716468fbfff7cf890c74bb7.shtml.
[4] Guan WJ, Ni ZY, Hu Y, et al.Clinical characteristics of coronavirus disease 2019 in China[J].N Engl J Med, 2020,382(18):1708-1720.
[5] 国家卫生健康委员会,国家中医药管理局. 新型冠状病毒肺炎诊疗方案(试行第七版)[Z]. 2020-03-03.
[6] Zhu N, Zhang D, Wang W, et al.A novel coronavirus from patients with pneumonia in China 2019[J].N Engl J Med,2020,382(8):727-733.
[7] Xu X, Chen P, Wang J, et al.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J].Sci China Life Sci,2020,63(3):457-460.
[8] 戴志辉,高立冬,罗垲炜,等.湖南省新型冠状病毒肺炎临床特征分析[J].实用预防医学,2020,27(4):396-399.
[9] Guo L, Wei D, Zhang X,et al.Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA S core[J].Front Microbiol, 2019,10:2752.
[10] Xu Z,Shi L,Wang Y,et al. Pathological findings of COVID- 19 associated with acute respiratory distress syndrome[J].Lancet Respir Med,2020,8(4):420-422.
[11] Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 6736(20):1-7.
[12] 邹文彬,宋斌,吴骁伟.重症新型冠状病毒肺炎并发急性肺栓塞1例报告并文献复习[J].武汉大学学报(医学版),2020,41(3):369-372.
[13] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组,等.新型冠状病毒肺炎相关静脉血栓栓塞症防治建议(试行)[J] .中华医学杂志,2020,100(11):808-813.
[14] La Gruta NL, Kedzierska K, Stambas J,et al. Aquestion of self-preservation: immunopathology in influenza virus infection[J].Immunol Cell Biol, 2007, 85(2):85-92.
[15] Younan P, Iampietro M, Nishida A,et al.Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm[J].mBio, 2017, 8(5):e00845-17.
[16] Li X, Wang L, Gong Z, et al. Clinical characteristics of 25 death cases infected with COVID-19 pneumonia:aretrospective review of medical records in a single medical center,Wuhan, China[J].medRxiv,2020.02.19.20025239. https://doi.org/10.1101/2020.02.19.20025239.